CYDY - Philippines OKs use of CytoDyn's leronlimab in COVID-19

CytoDyn (CYDY) announces that the Republic of the Philippines, Department of Health, Food and Drug Administration has approved the use of leronlimab to treat a COVID-19 patient under Compassionate Special Permit ((CSP)) pursuant to FDA Order No. 2016-005. The Company is shipping leronlimab to its partner, Chiral Pharma, its importer in the Philippines. Chiral Pharma is in ongoing discussions with the Philippines FDA to obtain EUA approval for leronlimab in COVID-19.The company will also seek CSP approval for leronlimab for COVID-19 long-hauler patients in the Philippines.Earlier this month, CYDY's leronlimab failed to improve survival in COVID-19 patients.Also in March, CytoDyn initiated patient enrollment in Phase 2 long-haulers COVID-19 trial.

For further details see:

Philippines OKs use of CytoDyn's leronlimab in COVID-19